REE/1654 7750

## REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for the continued exact matter of a utility or plant application filed on or after June 8, 1995.

DEC 0 1 2004 25

Application Number	09/663,709	
Filing Date	September 18, 2000	
First Named Inventor	FUJITA, Hiroyuki	
Group Art Unit	1654	
Name of Examiner	Anish Gupta	
Attorney Docket No.	001200	

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

Note: 37 C.F.R. §1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. §1.53 (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar 20, 2000) 1233 Off. Gazette Pat Office (April 11, 2000) which established RCE practice.

a.		Submission Required Under 37 C.F.R. § 1.114  Previously submitted				
	i.		Consider the amendment(s)/reply under 37 C.F.R. §1 (Any unentered amendment(s) referred to above will be entered)	.116 previously filed on	_	
	ii.		Consider the arguments in the Appeal Brief or Reply	Brief previously filed on		
	iii.		Other			
<b>b</b> .	×	Er	nclosed			
	i.	$\boxtimes$	Amendment/Reply			
	ii.		Affidavit(s)/Declaration(s)			
	iii.		Information Disclosure Statement (IDS)			
	iv.		Other			
2.	Mis	cella	neous			
		usper	neous sion of Action on the above-identified application is r months (period shall not exceed three months;	•	a period of	
а.	□ s	usper	sion of Action on the above-identified application is r	Fee under 37 C.F.R. §1.17(i) required)	a period of	
2. a. b. 3.	□ s	usper  her	sion of Action on the above-identified application is r months (period shall not exceed three months;	Fee under 37 C.F.R. §1.17(i) required)	a period of	
a. b. 3.	□ s □ ot Fee	usper her _ es T	sion of Action on the above-identified application is r months (period shall not exceed three months;	Fee under 37 C.F.R. §1.17(i) required)  C.F.R. §1.114 when the RCE is filed.		
a. b. 3.	□ S □ Ot Fee	usper her _ es T he Co	esion of Action on the above-identified application is remainder months (period shall not exceed three months;  the RCE fee under 37 C.F.R. §1.17(e) is required by 37 commissioner is hereby authorized to charge the follow	Fee under 37 C.F.R. §1.17(i) required)  C.F.R. §1.114 when the RCE is filed.	o Deposit	
a. b. 3.	S S S S S S S S S S S S S S S S S S S	usper her _  The Co Accou	nsion of Action on the above-identified application is remainder months (period shall not exceed three months;  the RCE fee under 37 C.F.R. §1.17(e) is required by 37 commissioner is hereby authorized to charge the followant No. 01-2340.	Fee under 37 C.F.R. §1.17(i) required)  C.F.R. §1.114 when the RCE is filed.  ing fees, or credit any overpayments, t	o Deposit	
a. b.	S S S S S S S S S S S S S S S S S S S	her The Co Accou	esion of Action on the above-identified application is remainder a months (period shall not exceed three months;  the RCE fee under 37 C.F.R. §1.17(e) is required by 37 commissioner is hereby authorized to charge the followent No. 01-2340.  CE fee required under 37 C.F.R. § 1.17 (e)	Fee under 37 C.F.R. §1.17(i) required)  C.F.R. §1.114 when the RCE is filed.  ing fees, or credit any overpayments, t  12/02/2004 HDERESS1 00000062 09663	o Deposit 709	

## REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for the continued examination of a utility or plant application filed on or after June 8, 1995.

PAGE 2



PATENT TRADEMARK OFFICE

Atty Docket No.

001200

SIGNATURE BY APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Name Daniel A. Geselowitz, Ph.D.	Registration No. 42,573 (agent)			
Signature Carrel a Descript Da	ate December 1, 2004			
CERTIFICATE OF	F MAILING OR TRANSMISSION			
	with the United States Postal Service as first class mail in an envelope Washington, D.C. 20231, or facsimile transmitted to the U.S. Patent and			
Name				
Signature				